This situation has concluded
It was preserved as a record on September 4; the timeline below shows how it unfolded, with sources. Get the briefing to follow the top situations still developing: three emails a week, sourced and in order.
Unsubscribe anytime.
[SITUATION] · [QUIET] · [BUSINESS]
2 clusters · 22 sources · 8 days · First seen · Last updated
Eli Lilly Q2 2026 earnings and revenue surge
Overview
Eli Lilly’s shares rose modestly on July 28, 2026 after analysts lifted price targets ahead of its earnings release. The company posted Q2 2026 non‑GAAP earnings of $8.38 per share, well above the $6.07 consensus, and revenue of about $23 billion – a 48 % year‑over‑year increase driven by its obesity‑treatment portfolio. Sales of the diabetes drug Mounjaro jumped 91 % to $9.9 billion and the weight‑loss drug Zepbound grew 44 % to $4.9 billion, together accounting for roughly two‑thirds of quarterly revenue. Worldwide realized prices for the GLP‑1 medicines fell 13 % (3 % in the United States, 36 % outside) after Mounjaro entered China’s national reimbursement list. Adjusted net income rose 32 % to $7.5 billion, prompting Lilly to raise its full‑year 2026 revenue outlook to $85‑$87 billion and reaffirm its EPS target. In the same quarter Lilly launched an oral obesity pill, Foundayo, which generated $98 million in sales, short of the $105.6 million analysts had expected.
Entities
Eli Lilly and Company · Excelsior Advisor Network LLC · China National Reimbursement Drug List · Tilray Brands · UGI Corporation
Claims
What the coverage asserts, and how many sources carry each claim.
- [● 7 SOURCES] Eli Lilly's second‑quarter 2026 revenue was $23 billion, up 48 percent year over year.
- [● 7 SOURCES] Mounjaro sales were $9.9 billion, up 91 percent year over year.
- [● 7 SOURCES] Zepbound sales were $4.9 billion, up 44 percent year over year.
- [● 7 SOURCES] Obesity drugs accounted for about two‑thirds of Eli Lilly's quarterly revenue.
- [● 6 SOURCES] Eli Lilly raised its full‑year 2026 revenue forecast to $85‑87 billion.
- [○ 1 SOURCE] UGI reported GAAP diluted EPS of –$0.62 for the quarter.
- [○ 1 SOURCE] Hagerty posted an adjusted loss of $0.02 per share, beating the –$0.09 estimate.
- [○ 1 SOURCE] Northern Oil and Gas received a consensus Hold rating with a 12‑month target price of $30.63.
- [○ 1 SOURCE] Hudson Pacific reported core FFO of $0.35 per share, beating expectations.
- [○ 1 SOURCE] Genco Shipping declared a $0.80 per share dividend, a 433% increase year over year.
- [○ 1 SOURCE] Worldwide realized prices for Eli Lilly's weight‑loss drugs fell 13% year over year, with U.S. realized prices down 3% (about 9% excluding adjustments).
- [○ 1 SOURCE] The 36% price decline outside the United States was driven by Mounjaro’s addition to China’s National Reimbursement Drug List.
- [○ 1 SOURCE] Novo Nordisk’s oral Wegovy tablet has generated more than five million U.S. prescriptions since its launch.
- [○ 1 SOURCE] Lilly's newly launched oral obesity pill Foundayo generated $98 million in sales, below the $105.6 million expected by analysts.
Timeline
-
[BUSINESS] 20 sourcesEli Lilly Q2 Revenue Jumps 48% on Obesity Drug Sales
Eli Lilly’s Q2 revenue hit $23 billion, up 48%, led by Mounjaro ($9.9 bn) and Zepbound ($4.9 bn); obesity drugs now make up about two‑thirds of sales, prices fell 13% globally, and the full‑year outlook was nud
-
[BUSINESS] 4 sourcesEli Lilly shares rise 2.1% on analyst upgrades; MercadoLibre to report Q2 2026 earnings; Elicio Therapeutics forecasts a
Eli Lilly shares rose 2.1% as analysts lifted price targets; MercadoLibre will release Q2 2026 results on Aug 5; Elicio Therapeutics forecasts a Q2 2026 loss of $0.53 per share.
Sources
aijourn.com · bygumbygolly.com · elceo.com · finbold.com · gazeta.eu · heartofdublin.com · last10k.com · lesaffaires.com · lesinguliersete.fr · levisonenterprises.com · lopinion.fr · mommygearest.com · moneytimes.com.br · news.alphastreet.com · otravel.com · pharmexec.com · seekingalpha.com · seucreditodigital.com.br · shippingherald.com · stocknews.com · tekedia.com · valor.globo.com
This summary has been updated 5 times: see revision history